FINAL PEER updated– The Swygert Axis: A New Paradigm in Cytokine-Histamine Signaling, Chronic Inflammatory Disease, and Immune Equilibrium
FINAL PEER – The Swygert Axis: A New Paradigm in Cytokine-Histamine Signaling, Chronic Inflammatory Disease, and Immune Equilibrium
Author: John Stephen Swygert
Abstract
The Swygert Axis integrates histamine receptors (H1-H4), cytokine dynamics, viral latency, and mast cell behavior into a unified model for chronic inflammatory disease, rooted in the Swygert Theory of Everything AO (STOE-AO). Based on lived experience and analysis, it posits chronic illness (e.g., long COVID) as a cumulative immune burden disrupting equilibrium. A diagnostic ratio and therapeutic roadmap using antihistamines, anti-cytokines, and antivirals are proposed, linking immune balance to celestial equilibrium.
I. Introduction
Surviving a severe immune collapse revealed to me a patterned dysfunction, not random chaos. Mainstream immunology details histamine, cytokines, and mast cells [Galli, 1993] but lacks a unifying model for chronic diseases like long COVID. The Swygert Axis, grounded in STOE-AO’s encoded substrate [cite FINAL PEER – The Encoded Substrate], reframes this as an equilibrium failure across immune signaling.
II. The Swygert Axis
The axis balances four histamine receptors:
Chronic disease stems from:
The Swygert Axis reframes chronic disease as an equilibrium breakdown, offering a diagnostic and therapeutic model. Future work will quantify ratios, linking immune and celestial balance [cite FINAL – The Eclipse].
References
Author: John Stephen Swygert
Abstract
The Swygert Axis integrates histamine receptors (H1-H4), cytokine dynamics, viral latency, and mast cell behavior into a unified model for chronic inflammatory disease, rooted in the Swygert Theory of Everything AO (STOE-AO). Based on lived experience and analysis, it posits chronic illness (e.g., long COVID) as a cumulative immune burden disrupting equilibrium. A diagnostic ratio and therapeutic roadmap using antihistamines, anti-cytokines, and antivirals are proposed, linking immune balance to celestial equilibrium.
I. Introduction
Surviving a severe immune collapse revealed to me a patterned dysfunction, not random chaos. Mainstream immunology details histamine, cytokines, and mast cells [Galli, 1993] but lacks a unifying model for chronic diseases like long COVID. The Swygert Axis, grounded in STOE-AO’s encoded substrate [cite FINAL PEER – The Encoded Substrate], reframes this as an equilibrium failure across immune signaling.
II. The Swygert Axis
The axis balances four histamine receptors:
- H1: Inflammation, permeability [Simons, 1996].
- H2: Tolerance, cardiac effects [Sachs, 1995].
- H3: Neuroimmune signaling [Arrang, 1983].
- H4: Mast cell modulation [Thurmond, 2004].
Cytokines (e.g., IL-6, TNF-α) and latent viruses (e.g., HSV-1 [Kennedy, 2014]) interplay, with mast cells as regulators [Galli, 1993]. Equilibrium fails under cumulative burden (toxins, viral reactivation).
Chronic disease stems from:
- Environmental stressors (e.g., allergens).
- Viral reactivation (e.g., EBV).
- Cytokine feedback loops.
We propose, where $ C $ is cytokine load and $ I $ is immune capacity, with\frac{C}{I} \approx 1in disease states (e.g., long COVID).C/I \approx 1.5
- Antihistamines: H1 blockers reduce inflammation [Simons, 1996]; H4 modulators stabilize mast cells [Thurmond, 2004].
- Anti-Cytokines: Anti-IL-6, TNF-α agents calm loops [Hunter, 2019].
- Antivirals: Acyclovir suppresses latency [Whitley, 1986].
- Goal: Restore with low-toxicity targeting.
C/I \approx 1
The Swygert Axis reframes chronic disease as an equilibrium breakdown, offering a diagnostic and therapeutic model. Future work will quantify
C/IReferences
- Simons, F.E.R. “Histamine and H1-Receptor Antagonists.” Springer, 1996.
- Sachs, G., et al. “Histamine and Acid Secretion.” Gastroenterology, 1995.
- Arrang, J.M., et al. “H3 Receptors and Neurotransmitter Release.” Nature, 1983.
- Thurmond, R.L., et al. “H4 Receptor Opportunities.” Pharmacological Reviews, 2004.
- Kennedy, P.G.E. “Herpes Simplex Virus Latency.” FEMS Microbiology Reviews, 2014.
- Galli, S.J., et al. “Mast Cells in Disease.” New England Journal of Medicine, 1993.
- Hunter, C.A., et al. “Cytokine Storms.” Nature Reviews Immunology, 2019.
- Whitley, R.J. “Acyclovir Therapy.” New England Journal of Medicine, 1986.
Comments
Post a Comment